Q-omics provides the consensus-scored TMEM135 profile across patient tissues and cancer cell-line models. TMEM135 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM135 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, TMEM135 RNA expression shows 20,593 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where TMEM135 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM135 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM135 survival associations across molecular data types. TMEM135 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM135 RNA expression–survival associations across cancer types. High TMEM135 expression shows unfavorable associations in STAD, LIHC, ESCA and ACC, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM135 RNA expression.
This table summarizes TMEM135 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM135. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM135 shows lower tumor expression in THCA and READ and higher tumor expression in KIRC, STAD, LIHC and BLCA. The KIRC box plot shows higher TMEM135 RNA expression in tumor versus normal tissue (log2 FC = +0.901, t-test p < 0.001).
This table shows molecular features associated with TMEM135 in patient tissues and cancer cell lines. In patient samples, TMEM135 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM135 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
